Susquehanna International Group, LLP Kymera Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

  • $641 Billion
  • Q4 2024

Call Options

13 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2024

Feb 14, 2025
SELL
$39.06 - $51.84 $238,266 - $316,224
-6,100 Reduced 29.76%
14,400 $579,000
Q3 2024

Nov 14, 2024
BUY
$30.16 - $52.4 $618,280 - $1.07 Million
20,500 New
20,500 $970,000
Q1 2024

May 07, 2024
SELL
$22.9 - $43.57 $290,830 - $553,339
-12,700 Reduced 64.8%
6,900 $277,000
Q4 2023

Feb 14, 2024
BUY
$10.97 - $26.84 $48,268 - $118,096
4,400 Added 28.95%
19,600 $499,000
Q3 2023

Nov 14, 2023
BUY
$13.9 - $23.88 $2,780 - $4,776
200 Added 1.33%
15,200 $211,000
Q2 2023

Aug 11, 2023
SELL
$22.4 - $34.92 $4.59 Million - $7.15 Million
-204,700 Reduced 93.17%
15,000 $344,000
Q1 2023

May 16, 2023
SELL
$24.84 - $38.75 $1.36 Million - $2.12 Million
-54,800 Reduced 19.96%
219,700 $6.51 Million
Q4 2022

Feb 14, 2023
BUY
$19.57 - $30.92 $5.18 Million - $8.18 Million
264,600 Added 2672.73%
274,500 $6.85 Million
Q3 2022

Nov 14, 2022
BUY
$20.91 - $34.27 $207,009 - $339,273
9,900 New
9,900 $216,000
Q2 2022

Aug 15, 2022
SELL
$14.13 - $42.55 $114,453 - $344,655
-8,100 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$35.3 - $64.68 $109,429 - $200,508
3,100 Added 62.0%
8,100 $343,000
Q4 2021

Feb 14, 2022
SELL
$49.91 - $65.56 $1.09 Million - $1.44 Million
-21,900 Reduced 81.41%
5,000 $317,000
Q2 2021

Aug 11, 2021
BUY
$31.08 - $51.95 $836,052 - $1.4 Million
26,900 New
26,900 $1.31 Million

Others Institutions Holding KYMR

# of Institutions
186
Shares Held
65.6M
Call Options Held
49.6K
Put Options Held
17K
View Full List

About Kymera Therapeutics, Inc.

KYMR Quotes by TradingView
  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $1.73B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email